Home Featured Page 18

Featured

Latest

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

Pα+ Psychedelic Bulletin #183:

Transpersonal Connections, the Body’s Memory, and the Collaborative Nature of Consciousness

Bullish on Chaos: Matt Zorn on How Psychedelics Could Benefit from...

The War on Drugs: The DEA’s Attempt to Schedule DOI &...

The Potential of Buprenorphine, the Risks of Ketamine, and How Psychedelics...

Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects...

Regulation, Decriminalization, and Religious Freedom: Prop 122’s Challenges and Opportunities

Inside the FDA’s Psychedelics Journey: Javier Muniz, MD on Breakthroughs, Challenges,...

How Family Healing Shapes Veteran Recovery

1...171819...295 Page 18 of 295

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

SCOOP: PSFC’s $130M Roadmap to Shape the Future of Psychedelic Philanthropy

Pα+ Psychedelic Bulletin #183:

Transpersonal Connections, the Body’s Memory, and the Collaborative Nature of Consciousness

Bullish on Chaos: Matt Zorn on How Psychedelics Could Benefit from...

The War on Drugs: The DEA’s Attempt to Schedule DOI &...

The Potential of Buprenorphine, the Risks of Ketamine, and How Psychedelics...

Pα+ Psychedelic Bulletin #182: Psychedelics Insiders’ Trump 2.0 Wishlist; Doblin Reflects...

Regulation, Decriminalization, and Religious Freedom: Prop 122’s Challenges and Opportunities

Inside the FDA’s Psychedelics Journey: Javier Muniz, MD on Breakthroughs, Challenges,...

How Family Healing Shapes Veteran Recovery

EDITOR PICKS

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY